Cephalalgia : an international journal of headache
-
Randomized Controlled Trial Multicenter Study
Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache.
To determine the minimal clinically important change (MCIC) in Headache Impact Test-6 (HIT-6) score in patients with chronic tension-type headache (CTTH). ⋯ A clinically relevant improvement in patients with CTTH is reflected by a decrease of at least 8 points on the HIT-6.
-
Randomized Controlled Trial Multicenter Study
Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache.
The aim was to assess the performance of the Visual Analogue Scale (VAS) in patients recruited in a clinical trial with over the counter analgesics in headache. ⋯ This study shows that the VRS categories cannot be presented in an equidistant manner on the VAS, and that contrary to previous assumptions, the pain intensity descriptors are less clear and can have different meanings in different languages. Therefore, both in the 3rd edition of the International Headache Classification (ICHD-III) and in the guidelines for clinical trials of patients with headache illnesses, rather than a 4-grade VRS, a 6-grade or higher level VRS or a VAS should be recommended, with correspondingly broadly defined anchor points.
-
Randomized Controlled Trial Multicenter Study
The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.
We investigated efficacy and tolerability of two tablets of the fixed combination of 250 mg acetylsalicylic acid (ASA) + 200 mg paracetamol + 50 mg caffeine (Thomapyrin) in comparison to two tablets of placebo in a post-hoc analysis of a subgroup of patients with severe headache. ⋯ The results of this subgroup analysis confirm that the fixed combination of ASA (250 mg), paracetamol (200 mg), and caffeine (50 mg) is effective and well tolerated in a broad spectrum from mild to severe migraine and tension-type headache severity independently of the headache diagnosis.
-
Randomized Controlled Trial Multicenter Study
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. ⋯ Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
-
Randomized Controlled Trial Multicenter Study
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.
Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. ⋯ The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.